NEW VACCINE APPROVED FOR DENGUE. HOW DOES IT WORK? WHAT IS THE COST ? WHAT IS THE TRADE NAME?
Searching the Web
new dengue vaccine approved 2025 2026 trade name cost mechanism
Searching PubMed
dengue vaccine approved 2024 2025
Reading File
Searching the Web
QDENGA Takeda dengue vaccine India approved July 2026 cost price mechanism of action
Searching the Web
Butantan dengue vaccine Brazil suspended 2026 details single dose
Reading Web Page
https://www.hindustantimes.com/ht-explainers/india-approves-…
Here is a full, up-to-date breakdown on the newly approved dengue vaccine:
QDENGA (TAK-003) - India's First Approved Dengue Vaccine
Approved: July 2026 - the Drug Controller General of India (DCGI) granted market authorisation to Takeda Biopharmaceuticals India's dengue vaccine, making it the first dengue vaccine approved in India.
Trade Name
QDENGA (generic name: TAK-003, also called Dengue Tetravalent Vaccine - DTV)
How It Works - Mechanism of Action
QDENGA is a live-attenuated tetravalent dengue vaccine. Here's how it works:
- Live-attenuated means it contains weakened but live versions of the dengue virus - too weak to cause disease, but strong enough to trigger immunity (same platform as measles, mumps, rubella/MMR, yellow fever, and oral polio vaccines).
- Tetravalent means it covers all four dengue serotypes (DENV-1, DENV-2, DENV-3, and DENV-4), each capable of independently causing dengue.
- DENV-2 backbone: The vaccine uses the DENV-2 serotype as its genetic backbone. The genetic sequences coding for the outer proteins of DENV-1, DENV-3, and DENV-4 are inserted into this DENV-2 backbone - creating four distinct chimeric virus components in one shot.
- Balanced immunity: The key innovation is inducing "balanced" immunity to all four serotypes simultaneously, mimicking the immune profile of someone who has naturally recovered from dengue infection. This is critical because:
- A person infected with one serotype gets lifelong immunity to that type but only short-lived cross-protection against the other three.
- A second infection with a different serotype can trigger antibody-dependent enhancement (ADE) - a dangerous phenomenon where pre-existing antibodies paradoxically worsen illness.
- QDENGA's balanced four-serotype immunity is designed to prevent this.
Who Can Receive It
| Parameter | Detail |
|---|---|
| Approved age group (India) | 4 to 60 years |
| Dosing schedule | 2 doses, 3 months apart |
| Route | Subcutaneous injection |
| Prior dengue infection required? | No - can be given regardless of prior exposure |
| Pre-vaccination screening | Not required |
Efficacy
Based on the Phase 3 TIDES trial (DEN-301) with over 20,000 participants across 8 countries:
- Significant protection against symptomatic dengue
- Reduced risk of hospitalisation
- Approved by WHO and prequalified
Cost / Price
Takeda has not yet publicly announced the official price for India. Key pricing details so far:
- The vaccine will initially be available through private healthcare facilities in India
- Takeda expects QDENGA to become available in India in the first half of 2027
- Takeda has partnered with Biological E (Hyderabad) since 2024 to expand manufacturing, which may help bring down costs over time
- In comparison, in other markets QDENGA costs roughly $50-80 USD per dose (approximately Rs 4,000-6,700 per dose in private markets), though India-specific pricing hasn't been confirmed yet
Current Global Status
| Region | Status |
|---|---|
| India | Approved July 2026 (DCGI) |
| European Union | Approved December 2022 (EMA) |
| Indonesia, Thailand, Malaysia | Approved |
| Brazil, Argentina | Approved |
| UK | Approved |
| USA (FDA) | Under priority review (not yet approved) |
Important Note - Brazil's Butantan-DV Vaccine
A separate dengue vaccine worth knowing about: Butantan-DV (Brazil's single-dose tetravalent dengue vaccine based on the NIH TV003 platform) was approved by Brazil in November 2025 and represented the world's first single-dose dengue vaccine. However, according to the BMJ (2026) and UpToDate, Brazil suspended its rollout in June 2026 after two deaths and 42 serious adverse events (severe abdominal pain, persistent vomiting, and bleeding) among 501,044 vaccinees. Authorities noted there is not enough data yet to establish a definitive causal link, but the deployment remains paused as a precaution. This vaccine has not been approved in India.
Bottom line: QDENGA (TAK-003) is the newly approved dengue vaccine in India as of July 2026, using a live-attenuated tetravalent DENV-2-backbone platform offering balanced four-serotype protection without requiring pre-vaccination serology. Official India pricing is pending, but availability through private channels is expected in early 2027.
This is a shared conversation. Sign in to Orris to start your own chat.